Prevalence and treatment of dyslipidemia in canadian primary care: A retrospective cohort analysis
References (30)
- et al.
Mortality by cause for eight regions of the world: Global Burden of Disease Study
Lancet
(1997) - et al.
A method for comparing and combining cost-of-illness studies: An example from cardiovascular disease
Chronic Dis Can.
(2002) - et al.
Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: Summary ofthe 2003 update
CMAJ
(2003) - et al.
Are Canadian guidelines for cholesterol lowering in high-risk patients optimal?
Can J Cardiol.
(2005) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)
JAMA
(2001)- et al.
Cholesterol reduction yields clinical benefit: Impact of statin trials
Circulation
(1998) - et al.
Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and metaanalysis
BMJ
(2003) - et al.
Impact of guidelines on health care use for the management of dyslipidemia in two Canadian provinces, Alberta and Nova Scotia, from 1990 to 2001
Can J Cardiol.
(2004)
Management of high blood cholesterol levels in Nova Scotian adults: Comparison with the NCEP II and European clinical practice guidelines
Am J Manag Care.
Application of the 1998 Canadian cholesterol guidelines to a military population: Health benefits and cost effectiveness of improved cholesterol management
Can J Cardiol.
Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis
CMAJ
Lipid-lowering therapy with statins in high-risk elderly patients: The treatment-risk paradox
JAMA
Comparison of the prevalence of cardiovascular risk factors between Quebec and other Canadian provinces: The Canadian heart health surveys
Ethn Dis
Cited by (37)
Estimating the benefits of patient and physician adherence to cardiovascular prevention guidelines: The myhealthcheckup survey
2011, Canadian Journal of CardiologyCitation Excerpt :These data are also comparable to those from other Canadian surveys. Among those individuals treated for dyslipidemia in a 2000-2003 Southwestern Ontario survey conducted in physician offices,31 47% had LDL-C or a TC/HDL-C ratio above treatment targets, compared with 48% among MHC participants. The success in reaching hypertension treatment targets in the MyHealthCheckup study (63%) was also similar to the results observed in the much larger, randomly sampled Ontario Survey on the Prevalence and Control of Hypertension (65.7%).32
Use of a treatment optimization algorithm involving statin-ezetimibe combination aids in achievement of guideline-based low-density lipoprotein targets in patients with dyslipidemia at high vascular risk guideline-based undertaking to improve dyslipidemia management in Canada (GUIDANC)
2011, Canadian Journal of CardiologyUsefulness of Statin-Ezetimibe Combination to Reduce the Care Gap in Dyslipidemia Management in Patients With a High Risk of Atherosclerotic Disease
2009, American Journal of CardiologyCitation Excerpt :In this multicenter observational cohort of 2,577 Canadian patients with persistent hypercholesterolemia, 71% of subjects were successful at attaining LDL cholesterol levels <2.5 mmol/L (97 mg/dl) and 41% <2.0 mmol/L (77 mg/dl) through a 26-week comprehensive treatment regime with statins and ezetimibe. Inasmuch as poor LDL cholesterol control is often ascribed to clinical inertia,1–6 the latter finding was reassuring because this lower LDL cholesterol target was advocated in Canada in 200613 while enrollment for this study was still in progress. Nonetheless, the <50% achievement rate underscores the fact that successful dissemination of data from practice-changing trials and evidence-based guideline recommendations and narrowing of the care gap persist as challenges in primary care.